JPRN-UMIN000023464招募中2 期
A randomized phaseII study to evaluate quality of life after total gastrectomy using a linear stapler vs a circular stapler for esophagojejunostomy - Laparoscopic esophagojejunostomy with linear or circular stapler
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Other active cancer 2. Active infectious disease 3. Possibly pregnant, or breast feeding woman 4. Psychiatric disorder 5. Receiving steroids 6. Acute myocardial infarction within 6 months or unstable angina 7. Uncontrolled hypertension 8. Uncontrolled diabetes mellitus and receiving insulin treatment 9. Pulmonary disease requiring continuous oxygen therapy
研究者
相似试验
招募中
2 期
A randomized phase II study to evaluate quality of life after total gastrectomy using a linear stapler vs a circular stapler for esophagojejunostomyGastric cancerJPRN-jRCT1042180138Terashima Masanori50
已完成
2 期
A randomized phase II study for the evaluation of T cell depleted non-myeloablative allogeneic stem cell transplantation followed by early consolidation with lenalidomide or lenalidomide combined with bortezomib and subsequent DLI for patients with multiple myeloma in progression or relapse following first line therapyKahlers disease10035227Multiple MyelomaNL-OMON36688HOVO110
进行中（未招募）
不适用
/ASubjects affected by non-segmental vitiligoMedDRA version: 14.1Level: PTClassification code 10062080Term: Pigmentation disorderSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-000169-10-ITCLINUVEL PHARMACUETICALS LTD.60
进行中（未招募）
1 期
ocally Advanced or Metastatic Hepatocellular Carcinoma (HCC): Evaluation of the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with BudigalimabHepatocellular CarcinomaCTIS2022-502948-13-00Abbvie Deutschland GmbH & Co. KG120
进行中（未招募）
1 期
A study to evaluate the switch from prednisone to dexamethasone in prostate cancer patients being treated with abirateroneEUCTR2021-000943-30-ESSOGUG (Spanish Genitourinary Oncologic Group)110